Overall, the in vitro efficacy of HIF2α-CD27 PAMs in downregulating multiple oncogenic mechanisms and their clinical potential for ccRCC gene therapy are provided. This evidence concerns the gene CD27 and nonpapillary renal cell carcinoma.